Successful treatment of severe psoriasis with basiliximab, an interleukin-2 receptor monoclonal antibody
- 1 May 2000
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 25 (3), 195-197
- https://doi.org/10.1046/j.1365-2230.2000.00612.x
Abstract
T-cell mediated inflammation plays an important role in the aetiology of psoriasis. We describe a case of severe recalcitrant psoriasis responding well to combined cyclosporin and basiliximab (Simulect® Novartis Pharmaceuticals UK Ltd), an interleukin-2 receptor (IL-2R; CD25) chimeric monoclonal antibody.Keywords
This publication has 10 references indexed in Scilit:
- Administration of DAB389IL-2 to patients with recalcitrant psoriasis: A double-blind, phase II multicenter trialJournal of the American Academy of Dermatology, 1998
- DISPOSITION OF BASILIXIMAB, AN INTERLEUKIN-2 RECEPTOR MONOCLONAL ANTIBODY, IN RECIPIENTS OF MISMATCHED CADAVER RENAL ALLOGRAFTS1Transplantation, 1997
- Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipientsThe Lancet, 1997
- Soluble interleukin-2 receptor (sIL-2R) is a marker of disease activity in psoriasis: a comparison of sIL-2R, sCD27, sCD4, sCD8 and sICAM-1.Acta Dermato-Venereologica, 1996
- Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basisNature Medicine, 1995
- Psoriasis: a T-cell-mediated autoimmune disease induced by streptococcal superantigens?Immunology Today, 1995
- The Cytokine Network in Lesional and Lesion-Free Psoriatic Skin Is Characterized by a T-Helper Type 1 Cell-Mediated ResponseJournal of Investigative Dermatology, 1993
- Fluoxetine-Induced PsoriasisAnnals of Pharmacotherapy, 1992
- Interleukin 2 and PsoriasisArchives of Dermatology, 1988
- Interleukin 2 and psoriasisArchives of Dermatology, 1988